One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in japanese chronic kidney disease patients undergoing hemodialysis

Therapeutic Apheresis and Dialysis

Volumn 14, Issue 1, 2010, Pages 12-19

  Shigematsu, Takashi ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Calcium phosphate product; Hyperphosphatemia; Lanthanum carbonate; Phosphate binder; Vitamin D

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; LANTHANUM CARBONATE; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHATE; PLACEBO; VITAMIN D;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ACUTE HEART INFARCTION; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE TURNOVER; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; ELECTROCARDIOGRAM; FEMALE; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; IRON DEFICIENCY ANEMIA; JAPANESE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PARATHYROID HORMONE BLOOD LEVEL; PATIENT MONITORING; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; SIDE EFFECT; STOMACH DISCOMFORT; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS; VITAL SIGN; VOMITING;

ABDOMINAL PAIN; ADULT; AGED; CALCIUM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERPHOSPHATEMIA; JAPAN; KIDNEY FAILURE, CHRONIC; LANTHANUM; MALE; MIDDLE AGED; NAUSEA; PARATHYROID HORMONE; PHOSPHATES; RENAL DIALYSIS; TREATMENT OUTCOME; VOMITING;

EID: 77149133062     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2009.00697.x     Document Type: Article

References (26)

1. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998 31 : 607 617.
2. Delmez JA, Slatopolsky E. Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis 1992 19 : 303 317.
3. Llach F, Yudd M. The importance of hyperphosphataemia in the severity of hyperparathyroidism and its treatment in patients with chronic renal failure. Nephrol Dial Transplant 1998 13 (Suppl. 3 57 61.
4. Rufino M, de Bonis E, Martin M et al. Is it possible to control hyperphosphataemia with diet, without inducing protein malnutrition? Nephrol Dial Transplant 1998 13 (Suppl. 3 65 7.
5. Albaaj F, Hutchison AJ. Lanthanum carbonate for the treatment of hyperphosphataemia in renal failure and dialysis patients. Expert Opin Pharmacother 2005 6 : 319 328.
6. Joy MS, Finn WF. Randomized, double-blind, placebo-controlled, dose-titration, Phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 2003 42 : 96 107.
7. Hutchison AJ, Speake M, Al-Baaj F. Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate. Nephrol Dial Transplant 2004 19 : 1902 1906.
8. Finn WF, Joy MS, Hladik G. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clin Nephrol 2004 62 : 193 201.
9. Chiang SS, Chen JB, Yang WC. Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease. Clin Nephrol 2005 63 : 461 470.
10. Al-Baaj F, Speake M, Hutchison AJ. Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study. Nephrol Dial Transplant 2005 20 : 775 782.
11. Hutchison AJ, Maes B, Vanwalleghem J et al. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract 2005 100 : c8 19.
12. D'Haese PC, Spasovski GB, Sikole A et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl 2003 85 : S73 8.
13. Finn WF, Joy MS. A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis. Curr Med Res Opin 2005 21 : 657 664.
14. Freemont AJ, Hoyland JA, Denton J. The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease. Clin Nephrol 2005 64 : 428 437.
15. Spasovski GB, Sikole A, Gelev S et al. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrol Dial Transplant 2006 21 : 2217 2224.
16. Finn WF. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol 2006 65 : 191 202.
17. Hutchison AJ, Maes B, Vanwalleghem J et al. Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study. Nephron Clin Pract 2006 102 : c61 71.
18. Shigematsu T. Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis. Ther Apher Dial 2008 12 : 55 61.
19. Shigematsu T, Lanthanum Carbonate Group. Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia. Clin Nephrol 2008 70 : 404 410.
20. Nakai S, Wada A, Kitaoka T et al. An overview of regular dialysis treatment in Japan (as of 31 December 2004). Ther Apher Dial 2006 10 : 476 497.
21. Sperschneider H, Gunther K, Marzoll I, Kirchner E, Stein G. Calcium carbonate (CaCO3): an efficient and safe phosphate binder in haemodialysis patients? A 3-year study. Nephrol Dial Transplant 1993 8 : 530 534.
22. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000 342 : 1478 1483.
23. Malluche HH, Monier-Faugere MC. Risk of adynamic bone disease in dialyzed patients. Kidney Int Suppl 1992 38 : S62 7.
24. Pei Y, Hercz G, Greenwood C et al. Risk factors for renal osteodystrophy: a multivariant analysis. J Bone Miner Res 1995 10 : 149 156.
25. Chertow GM, Dillon MA, Amin N, Burke SK. Sevelamer with and without calcium and vitamin D: observations from a long-term open-label clinical trial. J Ren Nutr 2000 10 : 125 132.
26. Koiwa F, Onoda N, Kato H et al. Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan. Ther Apher Dial 2005 9 : 340 346.